Coloplast

693.4

DKK

-1 %

Less than 1K followers

COLO B

NASDAQ Copenhagen

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

-1%

-10.18%

-12.07%

-11.8%

-20.75%

-24.81%

-32.91%

-33.29%

+1,378.46%

Coloplast is a developer of products and services adapted for people with different medical conditions. The company's product portfolio consists of various care equipment and is mainly used in the areas of ostomy, incontinence, urology, and skin and wound care. Today, the company operates in a global market through its own sales channels. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

Market cap

158.23B DKK

Turnover

214.14M DKK

Revenue

27.03B

EBIT %

27.08 %

P/E

30.87

Dividend yield-%

3.17 %

Financial calendar

6/5

2025

Interim report Q2'25

19/8

2025

Interim report Q3'25

4/11

2025

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release2/4/2025, 12:12 PM

Coloplast A/S - Allocation of Share Options

Regulatory press release2/4/2025, 6:29 AM

Coloplast A/S - Interim Financial Report, Q1 2024/25

Press release1/22/2025, 9:32 AM

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET (correction)

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release1/21/2025, 2:08 PM

Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET

Regulatory press release12/11/2024, 2:54 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release12/5/2024, 4:11 PM

Coloplast A/S - Decisions at the Annual General Meeting 2024

Press release12/4/2024, 12:01 PM

Coloplast divests core Skin Care product portfolio

Press release11/14/2024, 1:22 PM

Kerecis included on the list of covered products for Diabetic Foot Ulcers in the final LCD policy

Regulatory press release11/12/2024, 11:00 AM

Coloplast A/S - Notice of Annual General Meeting 2024

Regulatory press release11/5/2024, 6:28 AM

Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24

Regulatory press release11/5/2024, 6:26 AM

Coloplast A/S - Full-Year Financial Results 2023/24

Regulatory press release11/5/2024, 6:00 AM

Coloplast A/S - Announcement no. 05/2024 - Coloplast expands Executive Leadership Team

Press release10/21/2024, 1:09 PM

Coloplast A/S - FY 2023/24 Earnings Release - Invitation for conference call on 5 November 2024 at 11.00 CET

Regulatory press release9/25/2024, 1:02 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release9/25/2024, 12:29 PM

Coloplast A/S - Financial Calendar 2024-25

Regulatory press release9/20/2024, 2:56 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release9/16/2024, 2:47 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release9/3/2024, 1:20 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release9/3/2024, 1:03 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Regulatory press release8/30/2024, 3:07 PM

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.